Galectin Therapeutics Inc (GALT) 5.22 $GALT
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Galectin Therapeutics Inc. To Contact Brower Piven Before The September 29, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Fri Aug 08, 9:30PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics Inc. ("Galectin"
(NASDAQ: GALT) publicly traded securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" .
Lifshitz & Miller Law Firm Announces Investigation of Cobalt International Energy, Inc., DreamWorks Animation SKG, Inc., Galectin Therapeutics, Inc., Impax Laboratories, Inc., Peoples Federal Bancshares, Inc. and Siuslaw Financial Group, Inc.
PR Newswire - Fri Aug 08, 1:15PM CDT
Cobalt International Energy, Inc.
Galectin Therapeutics' net loss narrows to USD3.7m in Q2 2014
M2 - Fri Aug 08, 6:38AM CDT
Therapeutic company Galectin Therapeutics (NasdaqCM:GALT) stated on Thursday that its net loss applicable to common stock was USD3.7m (USD0.17 per share, basic and diluted) for the three months ended 30 June 2014.
Galectin Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 4:30PM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the three and six months ended June 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galectin Therapeutics, Inc. and Certain Officers -- GALT
GlobeNewswire - Thu Aug 07, 9:57AM CDT
Pomerantz LLP has filed a class action lawsuit against Galectin Therapeutics, Inc. ("Galectin" or the "Company" (Nasdaq:GALT) and certain of its officers. The class action, filed in United States District Court, District of Nevada, and docketed under 14-cv-01287, is on behalf of a class consisting of all persons or entities who purchased Galectin securities between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
Lieff Cabraser Announces Class Action Litigation Against Galectin Therapeutics Inc. - GALT
Business Wire - Wed Aug 06, 6:26PM CDT
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the publicly traded securities of Galectin Therapeutics Inc. ("Galectin" or the "Company" (NasdaqCM:GALT) between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" .
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Galectin Therapeutics Inc.
PR Newswire - Wed Aug 06, 12:30PM CDT
Rigrodsky & Long, P.A.:
Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
GlobeNewswire - Tue Aug 05, 8:00AM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/573,442 titled "Composition of Novel Carbohydrate Drug for Treatment of Human Diseases." The patent covers composition and chemical structural claims for compounds that includes the Company's lead galectin inhibitor compound GR-MD-02 and will expire in December 2031.
Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Galectin Therapeutics, Inc. - GALT
GlobeNewswire - Mon Aug 04, 11:55AM CDT
Morgan & Morgan announces a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics, Inc. ("Galectin" or the "Company" (Nasdaq:GALT) securities between January 6, 2014 through July 28, 2014, inclusive (the "Class Period" .
SHAREHOLDER ALERT: Investigation on Behalf of Galectin Therapeutics Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Mon Aug 04, 9:32AM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company" (NASDAQ:GALT). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by the Company concerning Galectin's business and financial prospects.
Galectin Therapeutics Responds to Class Action Lawsuit
GlobeNewswire - Mon Aug 04, 7:04AM CDT
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, issued the following statement today.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galectin Therapeutics Inc. to Contact Brower Piven Before the September 29, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- GALT
GlobeNewswire - Fri Aug 01, 9:22PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics Inc. ("Galectin" (Nasdaq:GALT) publicly traded securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" .
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc.
Business Wire - Fri Aug 01, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq: GALT), if they purchased the Company's securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of Nevada.
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Galectin Therapeutics Inc. -- GALT
GlobeNewswire - Fri Aug 01, 7:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of all persons who purchased or otherwise acquired the securities of Galectin Therapeutics Inc. ("Galectin" or the "Company" (Nasdaq:GALT) during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
Attention Galectin Therapeutics Inc. Investors: Galectin Misled Investors According to a Recently Filed Class Action
PR Newswire - Fri Aug 01, 5:58PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galectin Therapeutics Inc. (NASDAQ: GALT) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Nevada. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between January 6, 2014 and July 28, 2014 (the "Class Period" . Galectin is a development stage company that researches and develops therapies for fibrotic disease and cancer.
Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit on Behalf of Galectin Therapeutics, Inc. Has Been Filed in the United States District Court for the District of Nevada -- GALT
GlobeNewswire - Fri Aug 01, 3:15PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics, Inc. ("Galectin" or the "Company" (Nasdaq:GALT) securities between January 6, 2014 through July 28, 2014, inclusive (the "Class Period" .
Barrack, Rodos & Bacine Announces Investigation Of Actions Of Galectin Therapeutics, Inc., Since July 2013
PR Newswire - Fri Aug 01, 11:14AM CDT
Barrack, Rodos & Bacine is investigating possible violations of the federal securities law, including unlawful insider trading, on behalf of purchasers of Galectin Therapeutics, Inc. ("Galectin" (NASDAQ: GALT) securities between July 9, 2013 and July 28, 2014.
Downgrade Alert for Galectin Therapeutic (GALT)
Comtex SmarTrend(R) - Fri Aug 01, 7:57AM CDT
Galectin Therapeutic (NASDAQ:GALT) was downgraded from Buy to Hold at Aegis today. The stock closed yesterday at $6.14 on volume of 1.1 million shares, above average daily volume of 642,000. Galectin Therapeutic share prices have moved between a 52-week high of $19.11 and a 52-week low of $1.60 and closed yesterday at 284% above that low price at $6.14 per share. The 200-day and 50-day moving averages have moved 0.44% lower and 1.84% lower over the past week, respectively.
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. -- GALT
GlobeNewswire - Thu Jul 31, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq:GALT), if they purchased the Company's securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of Nevada.
Harwood Feffer LLP Announces Investigation of Galectin Therapeutics Inc.
PR Newswire - Thu Jul 31, 7:30PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against Galectin Therapeutics Inc. ("Galectin" or the "Company" (NASDAQ: GALT) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Galectin Therapeutics Inc. To Contact Brower Piven Before The September 29, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Fri Aug 08, 9:30PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics Inc. ("Galectin"
(NASDAQ: GALT) publicly traded securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . Lifshitz & Miller Law Firm Announces Investigation of Cobalt International Energy, Inc., DreamWorks Animation SKG, Inc., Galectin Therapeutics, Inc., Impax Laboratories, Inc., Peoples Federal Bancshares, Inc. and Siuslaw Financial Group, Inc.
PR Newswire - Fri Aug 08, 1:15PM CDT
Cobalt International Energy, Inc.
Galectin Therapeutics' net loss narrows to USD3.7m in Q2 2014
M2 - Fri Aug 08, 6:38AM CDT
Therapeutic company Galectin Therapeutics (NasdaqCM:GALT) stated on Thursday that its net loss applicable to common stock was USD3.7m (USD0.17 per share, basic and diluted) for the three months ended 30 June 2014.
Galectin Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 4:30PM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the three and six months ended June 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galectin Therapeutics, Inc. and Certain Officers -- GALT
GlobeNewswire - Thu Aug 07, 9:57AM CDT
Pomerantz LLP has filed a class action lawsuit against Galectin Therapeutics, Inc. ("Galectin" or the "Company"
(Nasdaq:GALT) and certain of its officers. The class action, filed in United States District Court, District of Nevada, and docketed under 14-cv-01287, is on behalf of a class consisting of all persons or entities who purchased Galectin securities between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . Lieff Cabraser Announces Class Action Litigation Against Galectin Therapeutics Inc. - GALT
Business Wire - Wed Aug 06, 6:26PM CDT
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the publicly traded securities of Galectin Therapeutics Inc. ("Galectin" or the "Company"
(NasdaqCM:GALT) between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Galectin Therapeutics Inc.
PR Newswire - Wed Aug 06, 12:30PM CDT
Rigrodsky & Long, P.A.:
Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
GlobeNewswire - Tue Aug 05, 8:00AM CDT
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/573,442 titled "Composition of Novel Carbohydrate Drug for Treatment of Human Diseases." The patent covers composition and chemical structural claims for compounds that includes the Company's lead galectin inhibitor compound GR-MD-02 and will expire in December 2031.
Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Galectin Therapeutics, Inc. - GALT
GlobeNewswire - Mon Aug 04, 11:55AM CDT
Morgan & Morgan announces a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics, Inc. ("Galectin" or the "Company"
(Nasdaq:GALT) securities between January 6, 2014 through July 28, 2014, inclusive (the "Class Period" . SHAREHOLDER ALERT: Investigation on Behalf of Galectin Therapeutics Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Mon Aug 04, 9:32AM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company"
(NASDAQ:GALT). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by the Company concerning Galectin's business and financial prospects. Galectin Therapeutics Responds to Class Action Lawsuit
GlobeNewswire - Mon Aug 04, 7:04AM CDT
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, issued the following statement today.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Galectin Therapeutics Inc. to Contact Brower Piven Before the September 29, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- GALT
GlobeNewswire - Fri Aug 01, 9:22PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics Inc. ("Galectin"
(Nasdaq:GALT) publicly traded securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc.
Business Wire - Fri Aug 01, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq: GALT), if they purchased the Company's securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of Nevada. Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Galectin Therapeutics Inc. -- GALT
GlobeNewswire - Fri Aug 01, 7:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of all persons who purchased or otherwise acquired the securities of Galectin Therapeutics Inc. ("Galectin" or the "Company"
(Nasdaq:GALT) during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . Attention Galectin Therapeutics Inc. Investors: Galectin Misled Investors According to a Recently Filed Class Action
PR Newswire - Fri Aug 01, 5:58PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galectin Therapeutics Inc. (NASDAQ: GALT) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Nevada. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between January 6, 2014 and July 28, 2014 (the "Class Period"
. Galectin is a development stage company that researches and develops therapies for fibrotic disease and cancer. Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit on Behalf of Galectin Therapeutics, Inc. Has Been Filed in the United States District Court for the District of Nevada -- GALT
GlobeNewswire - Fri Aug 01, 3:15PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Galectin Therapeutics, Inc. ("Galectin" or the "Company"
(Nasdaq:GALT) securities between January 6, 2014 through July 28, 2014, inclusive (the "Class Period" . Barrack, Rodos & Bacine Announces Investigation Of Actions Of Galectin Therapeutics, Inc., Since July 2013
PR Newswire - Fri Aug 01, 11:14AM CDT
Barrack, Rodos & Bacine is investigating possible violations of the federal securities law, including unlawful insider trading, on behalf of purchasers of Galectin Therapeutics, Inc. ("Galectin"
(NASDAQ: GALT) securities between July 9, 2013 and July 28, 2014. Downgrade Alert for Galectin Therapeutic (GALT)
Comtex SmarTrend(R) - Fri Aug 01, 7:57AM CDT
Galectin Therapeutic (NASDAQ:GALT) was downgraded from Buy to Hold at Aegis today. The stock closed yesterday at $6.14 on volume of 1.1 million shares, above average daily volume of 642,000. Galectin Therapeutic share prices have moved between a 52-week high of $19.11 and a 52-week low of $1.60 and closed yesterday at 284% above that low price at $6.14 per share. The 200-day and 50-day moving averages have moved 0.44% lower and 1.84% lower over the past week, respectively.
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. -- GALT
GlobeNewswire - Thu Jul 31, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq:GALT), if they purchased the Company's securities during the period between January 6, 2014 and July 28, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of Nevada. Harwood Feffer LLP Announces Investigation of Galectin Therapeutics Inc.
PR Newswire - Thu Jul 31, 7:30PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against Galectin Therapeutics Inc. ("Galectin" or the "Company"
(NASDAQ: GALT) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws. 
